# Combined Modality Treatment for Patients With Stage IV Melanoma

> **NCT00313235** · PHASE1,PHASE2 · COMPLETED · sponsor: **Baylor Research Institute** · enrollment: 41 (actual)

## Conditions studied

- Malignant Melanoma Stage IV

## Interventions

- **BIOLOGICAL:** DC Vaccine and Cyclophosphamide

## Key facts

- **NCT ID:** NCT00313235
- **Lead sponsor:** Baylor Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2011-06
- **Final completion:** 2012-06
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2013-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00313235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00313235, "Combined Modality Treatment for Patients With Stage IV Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00313235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*